Attachment
Fauci Intelligence Community Release, p.72 · fauci_intel:exh:00023
Page text: p.72 · original PDF
- Date
- — (unknown precision)
- Type
- attachment · document
The utility of certain countermeasures can be extrapolated from the
documents:
The team selected for SARSr-CoVs that were most monoclonal antibody
and vaccine resistant.
It is not practical to inoculate bats directly with shots, nor can
bats get respiratory infections from droplets, so the team
developed an aerosol to deliver the inoculations directly into the
caves. To ensure it worked well, they developed the aerosol against
masked civets.
The proposal notes that interferon, Remdesivir, and chloroquine
phosphate inhibit SARSr-CoV viral replication.
Because of its (now) known nature, the SARSr-CoV-WIV's illness is readily
resolved with early treatment that inhibits the viral replication that
spreads the spike proteins around the body (which induce a harmful
overactive immune response as the body tries to clear the spikes from
the ACE2 receptors). Many of the early treatment protocols ignored by
the authorities work because they inhibit viral replication or modulate
the immune response to the spike proteins, which makes sense within the
context of what EcoHealth was creating. Some of these treatment protocols
also inhibit the action of the engineered spike protein. For instance,
Ivermectin (identified as curative in April 2020) works throughout all
phases of illness because it both inhibits viral replication and
modulates
the
immune
response.
Of
note,
chloroquine
phosphate
(Hydroxychloriquine, identified April 2020 as curative) is identified
in the proposal as a SARSr-CoV inhibitor, as is interferon (identified
May 2020 as curative).
The gene-encoded, or "mRNA," vaccines work poorly because they are
synthetic replications of the already-synthetic SARSr-CoV-WIV spike
proteins and possess no other epitopes. The mRNA instructs the cells to
produce synthetic copies of the SARSr-CoV-WIV synthetic spike protein
directly into the bloodstream, wherein they spread and produce the same
ACE2 immune storm that the recombinant vaccine does. Many doctors in the
country have identified that the symptoms of vaccine reactions mirror
the symptoms of the disease, which corroborates with the similar
synthetic nature and function of the respective spike proteins.
The vaccine recipient has no defense against the bloodstream entry, but
their nose protects them from the recombinant spike protein quasispecies
during "natural infection" (better termed as aerosolized inoculation).
For SHSGAC Use Only - SHSGAC_COVID_119th 011834